The ETF Explosion

P/E Ratios and How to Use Them

Is it PR or PE . . .

Rise of the Global Titans

Amazon, Google, etc.

AIM Shares Reborn

AIM . . .

I’ll now drop in a Read More tag: Read more

History of the Bloomberg World Index

History of FTSE 100

Why are we waiting?

New Highs Corner, 22 June 2017

Abcam completes exciting acquisition

Latest price: 994.50p MV: £2.03bn  Next figures due: 11 September Web site:

Abcam, a Cambridge-based company, which supplies life sciences’ researchers with monoclonal antibodies (which are crucial to their work) has been on a roll since the company was founded early in the millennium. The shares were floated at 33.5p in 2005 and are fast-approaching £10. The shares marked time between 2011 and 2015 but have taken on a new lease of life after the company brought in Alan Hirzel, a former management consultant at Bain & Co, as chief marketing officer between 2013 and 2014 and CEO since September 2014. Profits are climbing again, the company is spreading its reach beyond antibodies into a wider range of proteins, it is using acquisitions to bring in expertise and benefiting from the weak £.